Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.21 | 0.18 | 0.21 | 0.19 | 0.19 | 0.18 | 0.19 | 0.19 | 0.19 | 0.19 | 0.37 | 0.20 |
| Operating Profit | -0.21 | -0.18 | -0.21 | -0.19 | -0.19 | -0.18 | -0.19 | -0.19 | -0.19 | -0.19 | -0.37 | -0.20 |
| OPM % | ||||||||||||
| Other Income | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Profit before tax | -0.19 | -0.22 | -0.25 | -0.23 | -0.23 | -0.18 | -0.23 | -0.23 | -0.23 | -0.23 | -0.37 | -0.24 |
| Tax % | -5.26% | -4.55% | 0.00% | -4.35% | -4.35% | 0.00% | 21.74% | -4.35% | -4.35% | -4.35% | -2.70% | 0.00% |
| Net Profit | -0.18 | -0.21 | -0.24 | -0.22 | -0.22 | -0.17 | -0.28 | -0.22 | -0.22 | -0.22 | -0.36 | -0.24 |
| EPS in Rs | -0.09 | -0.11 | -0.13 | -0.12 | -0.12 | -0.09 | -0.15 | -0.12 | -0.12 | -0.12 | -0.19 | -0.13 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.35 | 2.84 | 4.09 | 0.83 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 1.84 | 9.72 | 4.62 | 1.56 | 0.67 | 4.14 | 0.71 | 0.95 | 0.80 | 0.77 | 0.95 | 0.95 |
| Operating Profit | -0.49 | -6.88 | -0.53 | -0.73 | -0.67 | -4.14 | -0.68 | -0.95 | -0.80 | -0.77 | -0.95 | -0.95 |
| OPM % | -36.30% | -242.25% | -12.96% | -87.95% | -2,266.67% | |||||||
| Other Income | 0.00 | 0.03 | 0.06 | 0.02 | 0.01 | 0.20 | 0.26 | 0.02 | 0.09 | 0.05 | 0.04 | 0.04 |
| Interest | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.62 | 0.59 | 0.59 | 0.59 | 0.57 | 0.56 | 0.51 | 0.15 | 0.15 | 0.15 | 0.15 | 0.16 |
| Profit before tax | -1.19 | -7.44 | -1.06 | -1.30 | -1.23 | -4.50 | -0.93 | -1.08 | -0.86 | -0.87 | -1.06 | -1.07 |
| Tax % | -0.84% | -0.81% | -17.92% | -3.85% | -5.69% | -1.78% | -84.95% | -1.85% | -2.33% | 3.45% | -3.77% | |
| Net Profit | -1.19 | -7.39 | -0.87 | -1.25 | -1.17 | -4.42 | -0.14 | -1.05 | -0.83 | -0.90 | -1.02 | -1.04 |
| EPS in Rs | -0.62 | -3.87 | -0.46 | -0.65 | -0.61 | -2.31 | -0.07 | -0.55 | -0.43 | -0.47 | -0.53 | -0.56 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | % | % | % | ||
| Compounded Profit Growth | 1% | 12% | 1% | -17% | ||
| Stock Price CAGR | -8% | 11% | -6% | 0% | ||
| Return on Equity | -30% | -34% | -61% | -177% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15.03 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 |
| Reserves | 4.17 | -0.13 | -7.50 | -8.35 | -9.58 | -10.75 | -15.16 | -15.29 | -16.32 | -17.14 | -18.03 | -19.04 |
| Borrowings | 7.78 | 6.65 | 2.90 | 2.90 | 2.51 | 2.53 | 5.68 | 5.81 | 6.77 | 7.27 | 7.46 | 7.52 |
| Other Liabilities | 5.38 | 2.94 | 6.41 | 5.49 | 5.52 | 5.52 | 1.67 | 0.53 | 0.63 | 0.70 | 0.80 | 0.88 |
| Total Liabilities | 32.36 | 28.57 | 20.92 | 19.15 | 17.56 | 16.41 | 11.30 | 10.16 | 10.19 | 9.94 | 9.34 | 8.47 |
| Fixed Assets | 8.21 | 7.64 | 7.06 | 6.47 | 5.88 | 5.26 | 4.68 | 4.17 | 4.14 | 4.01 | 3.83 | 3.66 |
| CWIP | 6.15 | 6.15 | 5.51 | 5.21 | 5.43 | 5.02 | 3.90 | 3.42 | 3.40 | 3.26 | 2.91 | 2.41 |
| Investments | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 |
| Other Assets | 17.08 | 13.86 | 7.43 | 6.55 | 5.33 | 5.21 | 2.18 | 2.03 | 2.11 | 2.13 | 2.06 | 1.86 |
| Total Assets | 32.36 | 28.57 | 20.92 | 19.15 | 17.56 | 16.41 | 11.30 | 10.16 | 10.19 | 9.94 | 9.34 | 8.47 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 2.16 | 1.25 | 0.37 | -0.34 | 0.61 | -0.49 | -0.93 | -4.34 | -0.87 | -0.63 | -0.57 | -0.59 |
| Cash from Investing Activity | -0.44 | -0.05 | 0.63 | 0.30 | -0.22 | 0.46 | 1.54 | 0.46 | -0.10 | 0.12 | 0.38 | 0.52 |
| Cash from Financing Activity | -1.75 | -1.19 | -0.98 | 0.00 | -0.39 | 0.03 | -0.61 | 3.88 | 0.96 | 0.51 | 0.18 | 0.07 |
| Net Cash Flow | -0.03 | 0.01 | 0.02 | -0.04 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | 1.72 | 1.20 | 1.00 | -0.04 | 0.39 | -0.04 | 0.22 | -3.88 | -0.97 | -0.51 | -0.19 | -0.07 |
| CFO/OP | 267% | -292% | -5% | 64% | -84% | 73% | 22% | 638% | 92% | 79% | 74% | 62% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 229.02 | 1,154.48 | 532.08 | 344.47 | 1,147.77 | 365.00 | ||||||
| Inventory Days | 274.40 | 6,543.93 | 50.05 | 58.94 | 253.72 | 4,015.00 | 4,562.50 | |||||
| Days Payable | 123.03 | 556.19 | 15.95 | 14.48 | 71.22 | 876.00 | 1,825.00 | |||||
| Cash Conversion Cycle | 380.39 | 7,142.22 | 566.19 | 388.94 | 1,330.27 | 3,504.00 | ||||||
| Working Capital Days | 208.74 | 1,724.96 | -115.67 | -87.46 | -848.73 | -49,396.67 | ||||||
| ROCE % | 0.58% | -4.22% | -37.07% | -7.53% | -10.12% | -10.73% | -45.61% | -9.66% | -11.26% | -9.15% | -9.79% | -13.14% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 35.89% | 35.89% | 35.89% | 35.89% | 35.89% | 35.89% | 35.89% | 35.89% | 35.89% | 35.89% | 35.89% | 35.89% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.58% | 0.58% | 0.58% | 0.58% | 0.58% | 0.58% | 0.58% |
| Public | 64.11% | 64.11% | 64.11% | 64.12% | 64.11% | 63.52% | 63.51% | 63.53% | 63.52% | 63.53% | 63.53% | 63.53% |
| No. of Shareholders | 4,454 | 4,435 | 4,414 | 4,398 | 4,386 | 4,397 | 4,422 | 4,445 | 4,433 | 4,425 | 4,419 | 4,409 |
Fundamentals
Market Cap₹ 3.98 Cr.
Current Price₹ 2.08
Book Value₹ 0.04
ROCE-13.1 %
ROE-177 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)%
Compounded Profit Growth (TTM)-17%
Standalone figures.
Valuation
Market capRs 4 Cr
Enterprise valueRs 11 Cr
Price to book56.79x
Earnings yield-26.16%
P/B, 3-year average17.96x
P/B, 5-year average11.21x
Profitability
ROE-177.39%
ROCE-13.14%
ROA-11.45%
ROE, 3-year average-90.43%
ROCE, 3-year average-10.69%
ROA, 3-year average-9.68%
ROE, 5-year average-61.33%
ROCE, 5-year average-10.60%
ROA, 5-year average-8.13%
ROIC (approx.)-13.57%
Tax rate3.77%
Other income / net worth57.14%
Per share
EPS (TTM)Rs -0.54
EPS (latest year)Rs -0.53
EPS (latest quarter)Rs -0.13
EPS, 3-year averageRs -0.47
EPS, 5-year averageRs -0.41
Book value per shareRs 0.04
Cash flow per shareRs -0.31
Free cash flow per shareRs -0.04
Efficiency
Inventory turnover0.20x
Inventory days1825 days
Creditor days1825 days
Cash conversion cycle3504 days
Working capital days-49397 days
Leverage
Total debtRs 8 Cr
Net debtRs 8 Cr
Debt to equity107.43x
Owners' fund to total sources0.83%
Debt to assets88.78%
Cash flow
Cash from Operating Activity (latest year)Rs -1 Cr
Cash from Investing Activity (latest year)Rs 1 Cr
Cash from Financing Activity (latest year)Rs 0 Cr
Free cash flow (latest year)Rs -0 Cr
FCFE (approx.: FCF + change in debt)Rs -0 Cr
Statement figures
Operating profit (latest quarter)Rs -0 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs -1 Cr
PBDT (TTM)Rs -1 Cr
Profit before tax (TTM)Rs -1 Cr
Tax (latest year)Rs -0 Cr
Net profit (TTM)Rs -1 Cr
Net profit (latest year)Rs -1 Cr
Net profit (latest quarter)Rs -0 Cr
Depreciation (TTM)Rs 0 Cr
Depreciation (latest quarter)Rs 0 Cr
Cost of goods sold (latest year)Rs 0 Cr
Total income (latest year)Rs 0 Cr
Share capitalRs 19 Cr
ReservesRs -19 Cr
Shareholders' fundsRs 0 Cr
Total assetsRs 8 Cr
Net blockRs 4 Cr
Capital work in progressRs 2 Cr
InvestmentsRs 1 Cr
InventoryRs 0 Cr
Other liabilitiesRs 1 Cr
Shares outstanding (crore)1.91
Ownership
Promoter holding35.89% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/B 56.79 is at the 99th percentile (median 0.89).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 531686 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +9.5% | -2.8% | +12.3 pts |
| 3 years | -18.1% | +14.2% | -32.3 pts |
| 5 years | +71.9% | +27.9% | +44.0 pts |
Red flags
F-score 2 of 6| look | Repeated losses Net loss in each of the last two years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹0 Cr.
Net loss ₹0 Cr.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of MPS Pharmaa Ltd?
MPS Pharmaa Ltd (531686) has a market capitalisation of Rs 3.98 Cr. at the 2026-09-28 close.
What were MPS Pharmaa Ltd's latest quarterly results?
In the Jun 2026 quarter, MPS Pharmaa Ltd sales was Rs 0 Cr with a net loss of Rs 0 Cr.